 |
 |
 |
 |
 |
 |
 |
| © 2006 VistaGen Therapeutics, Inc. |
|
VistaGen Therapeutics is a biopharmaceutical company pioneering the use of embryonic stem cells (ES cells) for drug discovery and development and predictive toxicology. Proprietary ES Cell Platform
VistaGen's core R&D platform consists of novel and clinically-relevant ES cell technologies and associated bioinformatics systems. Our technologies enable the discovery and validation of disease- and pathway-specific proteins that are biological drugs and classical drug targets. VistaGen's novel ES cell biological systems are the basis for innovative custom pharmacology and toxicology screening systems. We believe that our ES cell systems will enable the identification of drug candidates with greater efficiency and higher probability of success compared to traditional approaches. With VistaGen's ES cell technologies, researchers utilize proprietary cell lines and customized differentiation protocols to create a wide range of clinically relevant cells at high efficiency and high purity, especially insulin-producing b-islet cells, dopamine-positive neurons, and cells of the heart, liver, blood and vascular organs. Toxicity Screening Tools
VistaGen's ES cell technologies provide human ES cell-based heart and liver cell systems that address the limitations of current biological systems and focus on the two most relevant cell types for toxicity testing. Additionally, VistaGen's ES cell technologies will enable researchers to assess how genetic differences of people could affect responses to new drugs. VistaGen's ES cell toxicology screening systems could also potentially reduce the number of animals used in drug development. |
Overview |
|
